HOTH - Hoth Therapeutics, Inc.

QQQ $ 604.92 $ 3.94 (0.66 %)

DIA $ 461.73 $ 2.22 (0.48 %)

SPY $ 665.28 $ 3.75 (0.57 %)

TLT $ 91.09 $ -0.14 (-0.15 %)

GLD $ 391.28 $ -7.46 (-1.88 %)

Previous Close

$ 1.4

Open

$ 1.42

Bid

$ 1.35 x 1

Ask

$ 1.56 x 290

Day's Range

$ 1.36 - $ 1.43

52 Week Range

$ 0.66 - $ 3.80

Volume

505,577

Average Volume

Market Cap

18.45M

Beta (5Y Monthly)

$ 0.56

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-12-2025	03-31-2025	10-Q
3	03-28-2025	12-31-2024	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-09-2024	06-30-2024	10-Q
6	05-14-2024	03-31-2024	10-Q
7	03-28-2024	12-31-2023	10-K
8	11-13-2023	09-30-2023	10-Q
9	08-11-2023	06-30-2023	10-Q
10	05-15-2023	03-31-2023	10-Q
11	03-31-2023	12-31-2022	10-K
12	11-10-2022	09-30-2022	10-Q
13	08-12-2022	06-30-2022	10-Q
14	05-12-2022	03-31-2022	10-Q
15	03-29-2022	12-31-2021	10-K
16	11-10-2021	09-30-2021	10-Q
17	08-11-2021	06-30-2021	10-Q
18	05-13-2021	03-31-2021	10-Q
19	03-16-2021	12-31-2020	10-K
20	11-10-2020	09-30-2020	10-Q
21	08-13-2020	06-30-2020	10-Q
22	05-13-2020	03-31-2020	10-Q
23	03-02-2020	12-31-2019	10-K
24	11-12-2019	09-30-2019	10-Q
25	08-14-2019	06-30-2019	10-Q
26	05-15-2019	03-31-2019	10-Q
27	04-01-2019	12-31-2018	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Hoth Therapeutics Expands Its AI Initiativ...
10/08/2025 14:24:38

Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its G...

Hoth Therapeutics To Present HT-001 And HT...
10/07/2025 12:00:06

Presentation to highlight advancements in Hoth's clinical pipeline, includingHT-001 for cancer-therapy-induced rash and HT-...

Hoth Therapeutics Expands Intellectual Pro...
09/24/2025 12:16:43

MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, ...

Hoth Therapeutics Provides Shareholder Upd...
09/16/2025 12:15:16

Hoth Therapeutics Approves Expansion Of Tr...
09/12/2025 12:28:24

-SEC Filing

Hoth Therapeutics Submits CTA To EMA To Ex...
09/10/2025 12:32:33

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clini...

12 Health Care Stocks Moving In Tuesday's ...
09/02/2025 21:06:39

Top 5 Biotech Stocks With Strong Momentum
08/28/2025 11:19:00

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

D. Boral Capital Maintains Buy on Hoth The...
08/18/2025 11:25:50

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.

D. Boral Capital Maintains Buy on Hoth The...
07/30/2025 11:34:48

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.

Hoth Therapeutics Engages With ICON Clinic...
07/29/2025 11:59:56

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countri...

D. Boral Capital Maintains Buy on Hoth The...
07/23/2025 11:10:07

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.

Hoth Therapeutics Announces CRADA With U.S...
07/22/2025 12:20:39

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and ...

D. Boral Capital Maintains Buy on Hoth The...
06/26/2025 11:16:13

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.

Hoth Therapeutics And Silo Pharma Form Str...
06/25/2025 12:29:49

*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Marke...

Hoth Therapeutics' HT-001 Achieves 100% Re...
06/24/2025 14:37:43

Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR In...

Hoth Therapeutics Regains Full Compliance ...
06/18/2025 17:36:23

Hoth Therapeutics Releases Preclinical Saf...
06/18/2025 12:24:32

HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT — Dose-Dependent Activity, No Toxicity, IND o...

Hoth Therapeutics Secures Japan Patent For...
06/12/2025 13:18:29

Protection through 2039, ensuring long-term commercial exclusivity.NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, I...

D. Boral Capital Maintains Buy on Hoth The...
06/12/2025 12:52:44

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.